MG
MCID: MYS003
MIFTS: 69

Myasthenia Gravis (MG)

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Myasthenia Gravis

MalaCards integrated aliases for Myasthenia Gravis:

Name: Myasthenia Gravis 57 11 19 42 52 58 75 28 53 41 43 14 36 16 71 31 33
Mg 57 42
Autoimmune Myasthenia Gravis 58
Mg - [myasthenia Gravis] 33
Myasthenia Gravis Nos 33
Erb-Goldflam Disease 33
Acquired Myasthenia 58
Myasthenia 33

Characteristics:


Inheritance:

Multigenic/multifactorial 58 , Usually sporadic 57

Prevelance:

1-9/100000 (Europe, Worldwide, Spain, United Kingdom, Serbia, Italy, Australia, Taiwan, Province of China, Estonia, Greece, Croatia, Egypt) 1-5/10000 (Europe, Canada, United Kingdom, United Kingdom, United States, Serbia, Austria, Italy, Australia, Taiwan, Province of China) 1-9/1000000 (United States, Greece, Croatia, Worldwide) 58

Age Of Onset:

All ages 58

Age Of Death:

normal life expectancy 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare eye diseases


Summaries for Myasthenia Gravis

MedlinePlus Genetics: 42 Myasthenia gravis is a disorder that causes weakness of the skeletal muscles, which are muscles that the body uses for movement. The weakness most often starts in the muscles around the eyes, causing drooping of the eyelids (ptosis) and difficulty coordinating eye movements, which results in blurred or double vision. In a form of the disorder called ocular myasthenia, the weakness remains confined to the eye muscles. In most people with myasthenia gravis, however, additional muscles in the face and neck are affected. Affected individuals may have unusual facial expressions, difficulty holding up the head, speech impairment (dysarthria), and chewing and swallowing problems (dysphagia) that may lead to choking, gagging, or drooling.Other muscles in the body are also affected in some people with myasthenia gravis. The muscles of the arms and legs may be involved, causing affected individuals to have changes in their gait or trouble with lifting objects, rising from a seated position, or climbing stairs. The muscle weakness tends to fluctuate over time; it typically worsens with activity and improves with rest.Weakness of the muscles in the chest wall and the muscle that separates the abdomen from the chest cavity (the diaphragm) can cause breathing problems in some people with myasthenia gravis. About 10 percent of people with this disorder experience a potentially life-threatening complication in which these respiratory muscles weaken to the point that breathing is dangerously impaired, and the affected individual requires ventilation assistance. This respiratory failure, called a myasthenic crisis, may be triggered by stresses such as infections or reactions to medications.People can develop myasthenia gravis at any age. For reasons that are unknown, it is most commonly diagnosed in women younger than age 40 and men older than age 60. It is uncommon in children, but some infants born to women with myasthenia gravis show signs and symptoms of the disorder for the first few days or weeks of life. This temporary occurrence of symptoms is called transient neonatal myasthenia gravis.

MalaCards based summary: Myasthenia Gravis, also known as mg, is related to neonatal myasthenia gravis and myasthenic syndrome, congenital, 6, presynaptic, and has symptoms including ptosis, diplopia and dysphagia. An important gene associated with Myasthenia Gravis is AKAP12 (A-Kinase Anchoring Protein 12), and among its related pathways/superpathways are Overview of interferons-mediated signaling pathway and NF-kappaB Signaling. The drugs Salbutamol and Eculizumab have been mentioned in the context of this disorder. Affiliated tissues include thymus, eye and skeletal muscle, and related phenotypes are ptosis and diplopia

MedlinePlus: 41 Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke

NINDS: 52 Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal muscles of the body, which are responsble for breathing and moving parts of the body, including the arms and legs. In myasthenia gravis, the immune system--which normally protects the body from foreign organisms--mistakenly attacks itself.   Symptoms vary in type and intensity, and may include: • muscle weakness in the arms, hands, fingers, legs and neck • weakness of the eye muscles • drooping eyelid • difficulty swallowing • shortness of breath • impaired speaking Myasthenia gravis is caused by an error in the transmission of nerve impulses to muscles. Antibodies (immune proteins produced by the body's immune system) block the normal activity of the neurotransmitter acetylcholine, which prevents muscles from contracting. The thymus gland also may give incorrect instructions to immune cells and cause the immune system to attack its own cells and tissues. .

OMIM®: 57 Myasthenia gravis is an autoimmune disease in which antibodies bind to acetylcholine receptors or to functionally related molecules in the postsynaptic membrane at the neuromuscular junction. The antibodies induce weakness of skeletal muscles, which is the sole disease manifestation. The weakness can be generalized or localized, is more proximal than distal, and nearly always includes eye muscles, with diplopia and ptosis. The pattern of involvement is usually symmetric, apart from the eye involvement, which is often markedly asymmetric and involves several eye muscles. The weakness typically increases with exercise and repetitive muscle use (fatigue) and varies over the course of a day and from day to day, often with nearly normal muscle strength in the morning (summary by Gilhus, 2016). (254200) (Updated 24-Oct-2022)

GARD: 19 Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. Common symptoms include weakness of the muscles that control the eye and eyelid, facial expressions, chewing, talking, and swallowing. Weakness tends to increase during periods of activity and improve after periods of rest. The condition results from a defect in the transmission of nerve impulses to muscles, which is due to the presence of antibodies against acetylcholine. The exact reason this occurs is not known. Some cases have been linked to tumors in the thymus gland. Some cases may go into remission temporarily, and muscle weakness may disappear so that medications can be discontinued.

Disease Ontology: 11 An autoimmune disease of the nervous system that has material basis in antibodies to acetylcholine receptors at the neuromuscular junction, has symptom ptosis, has symptom diplopia, has symptom dysphagia, has symptom dysarthria, has symptom muscle weakness and has symptom shortness of breath.

Orphanet: 58 Myasthenia gravis (MG) is a rare, clinically heterogeneous, autoimmune disorder of the neuromuscular junction characterized by fatigable weakness of voluntary muscles.

Wikipedia: 75 Myasthenia gravis (MG) is a long-term neuromuscular junction disease that leads to varying degrees of... more...

Related Diseases for Myasthenia Gravis

Diseases in the Myasthenia Gravis family:

Juvenile Myasthenia Gravis Adult-Onset Myasthenia Gravis

Diseases related to Myasthenia Gravis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1458)
# Related Disease Score Top Affiliating Genes
1 neonatal myasthenia gravis 32.9 RAPSN MUSK CHRNG AGRN
2 myasthenic syndrome, congenital, 6, presynaptic 32.8 RAPSN CHRNE ACHE
3 thymoma 32.7 TTN TNF RYR1 IL2 IL10 CTLA4
4 thymus cancer 32.5 TTN MUSK IL2 CTLA4 AIRE AGRN
5 congenital myasthenic syndrome 32.3 TTN RYR1 RAPSN MUSK CHRNG CHRNE
6 neuromyelitis optica 32.3 TNFSF13B MBP IL4
7 multiple pterygium syndrome, escobar variant 32.2 RYR1 RAPSN CHRNG CHRNA1
8 lambert-eaton myasthenic syndrome 32.0 TTN TNF MUSK IL10
9 ptosis 31.8 TTN RYR1 RAPSN MUSK CHRNG CHRNE
10 neuromuscular disease 31.8 TTN TMPO RYR1 RAPSN MUSK MBP
11 myositis 31.7 TTN TNF RYR1 IFNG
12 respiratory failure 31.6 TTN TNF RYR1 MUSK IL4 IL2
13 autoimmune disease 31.6 TTN TNFSF13B TNF MUSK MBP IL4
14 hypothyroidism 31.5 TNF IL4 IL2 CTLA4 AIRE
15 hashimoto thyroiditis 31.5 IL4 IFNG CTLA4 AIRE
16 graves' disease 31.5 IL4 IFNG CTLA4 AIRE
17 covid-19 31.4 TNF IL4 IL2 IL10
18 myocarditis 31.4 TTN TNF IL4 IL2 IL10 IFNG
19 pemphigus 31.4 TNFSF13B TNF IL4 IL10 CTLA4
20 graves ophthalmopathy 31.3 TNF IFNG CTLA4
21 graft-versus-host disease 31.3 TNF IL2 IL10 IFNG
22 myelitis 31.3 TNF MBP IL10
23 thyroiditis 31.3 TNF IL4 IL2 IL10 IFNG CTLA4
24 chronic inflammatory demyelinating polyradiculoneuropathy 31.2 MUSK MBP IFNG
25 demyelinating polyneuropathy 31.2 TNF MUSK MBP
26 internuclear ophthalmoplegia 31.2 MUSK MBP
27 vitiligo-associated multiple autoimmune disease susceptibility 1 31.2 TNF IL2 CTLA4 AIRE
28 neuromuscular junction disease 31.2 TTN RYR1 RAPSN MUSK CHRNG CHRNE
29 sarcoidosis 1 31.1 TNF IL2 IL10 IFNG
30 optic neuritis 31.1 TNF MBP IL10
31 viral infectious disease 31.1 TNF IL4 IL2 IL10 IFNG CTLA4
32 anemia, autoimmune hemolytic 31.1 TNFSF13B IL2 IL10 CTLA4
33 severe acute respiratory syndrome 31.1 TNF IL4 IL2 IL10 IFNG
34 alopecia 31.1 TNF IL4 IL2 IFNG CTLA4 AIRE
35 distal arthrogryposis 31.1 TTN RYR1 RAPSN MUSK CHRNG CHRNA1
36 neuritis 31.1 TNF MBP IL4 IL10 IFNG
37 systemic scleroderma 31.1 TNFSF13B TNF IL4 IL2 IL10
38 systemic lupus erythematosus 31.0 TNFSF13B TNF MBP IL4 IL2 IL10
39 amyotrophic lateral sclerosis 1 31.0 TNF MUSK MBP IL4 IL10 AKAP12
40 cholangitis 31.0 TNF IL2 IL10 CTLA4
41 muscular dystrophy 31.0 TTN TNF TMPO RYR1 AGRN ACHE
42 purpura 31.0 TNFSF13B TNF IL4 IL2 IL10 IFNG
43 ulcerative colitis 31.0 TNF IL4 IL2 IL10 IFNG
44 tetanus 31.0 TNF IL4 IL2 IL10 IFNG
45 pneumonia 31.0 TNF IL4 IL10 IFNG
46 polyradiculoneuropathy 30.9 MBP IL10 IFNG
47 severe covid-19 30.9 TNF IL4 IL2 IL10 IFNG
48 ocular motility disease 30.9 RYR1 RAPSN MUSK CHRNE
49 macs syndrome 30.9 TNF IL10 IFNG
50 autoimmune hepatitis 30.9 TNF IL10 IFNG CTLA4 AIRE

Graphical network of the top 20 diseases related to Myasthenia Gravis:



Diseases related to Myasthenia Gravis

Symptoms & Phenotypes for Myasthenia Gravis

Human phenotypes related to Myasthenia Gravis:

58 30 (show all 42)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ptosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0000508
2 diplopia 58 30 Frequent (33%) Frequent (79-30%)
HP:0000651
3 dysarthria 58 30 Frequent (33%) Frequent (79-30%)
HP:0001260
4 dysphagia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002015
5 dyspnea 58 30 Frequent (33%) Frequent (79-30%)
HP:0002094
6 ophthalmoparesis 58 30 Frequent (33%) Frequent (79-30%)
HP:0000597
7 myositis 58 30 Frequent (33%) Frequent (79-30%)
HP:0100614
8 bulbar palsy 58 30 Frequent (33%) Frequent (79-30%)
HP:0001283
9 abnormality of the thymus 58 30 Frequent (33%) Frequent (79-30%)
HP:0000777
10 single fiber emg abnormality 58 30 Frequent (33%) Frequent (79-30%)
HP:0030006
11 anti-acetylcholine receptor antibody positivity 30 Frequent (33%) HP:0030208
12 anti-muscle-specific tyrosine kinase antibody 30 Frequent (33%) HP:0030210
13 hearing impairment 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000365
14 hashimoto thyroiditis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000872
15 paresthesia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003401
16 hyperthyroidism 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000836
17 hyperacusis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010780
18 primary adrenal insufficiency 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0008207
19 raynaud phenomenon 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030880
20 rheumatoid arthritis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001370
21 systemic lupus erythematosus 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002725
22 glycosuria 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003076
23 acrocyanosis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001063
24 hepatitis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0012115
25 hemolytic anemia 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001878
26 psychosis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000709
27 pure red cell aplasia 58 30 Very rare (1%) Very rare (<4-1%)
HP:0012410
28 seizure 30 Very rare (1%) HP:0001250
29 seizures 58 Very rare (<4-1%)
30 facial palsy 30 HP:0010628
31 muscle weakness 58 Very frequent (99-80%)
32 autoimmunity 30 HP:0002960
33 abnormality of the immune system 30 HP:0002715
34 nasal speech 30 HP:0001611
35 abnormality of the endocrine system 30 HP:0000818
36 limb muscle weakness 30 HP:0003690
37 impaired mastication 30 HP:0005216
38 proximal muscle weakness 30 HP:0003701
39 fatigable weakness 30 HP:0003473
40 thymoma 30 HP:0100522
41 acetylcholine receptor antibody positivity 58 Frequent (79-30%)
42 muscle specific kinase antibody positivity 58 Frequent (79-30%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
H E E N T:
ptosis
diplopia
dysarthria
facial muscle weakness
difficulty chewing

Immunology:
autoimmunity
thymoma
antibodies to acetylcholine receptor (achr)
association with gm type

Muscle:
proximal limb muscle weakness.

Pulmonary:
ventilatory insufficiency

G I:
dysphagia

Voice:
nasal speech

Endocrine:
thyrotoxicosis

Misc:
childhood or adolescent onset
static or only slowly progressive

Clinical features from OMIM®:

254200 (Updated 24-Oct-2022)

Symptoms:

11
  • ptosis
  • diplopia
  • dysphagia
  • dysarthria
  • muscle weakness
  • shortness of breath

UMLS symptoms related to Myasthenia Gravis:


back pain; headache; pain; sciatica; seizures; syncope; tremor; chronic pain; muscle weakness; facial paresis; vertigo/dizziness; sleeplessness

GenomeRNAi Phenotypes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

25 (show all 46)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.07 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.07 TNFSF13B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.07 TMPO
4 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.07 RAPSN
5 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.07 CHRNA1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.07 IL10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.07 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.07 TMPO
9 Increased shRNA abundance (Z-score > 2) GR00366-A-141 10.07 TMPO
10 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.07 ACHE
11 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.07 TMPO
12 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.07 TNFSF13B
13 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.07 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-155 10.07 CHRNA1 RAPSN
15 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.07 ACHE IL10 MUSK TNFSF13B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.07 TMPO
17 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.07 CHRNA1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-175 10.07 MUSK
19 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.07 AIRE
20 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.07 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.07 MUSK
22 Increased shRNA abundance (Z-score > 2) GR00366-A-204 10.07 ACHE
23 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.07 TMPO MUSK
24 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.07 IL10
25 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.07 ACHE IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.07 RAPSN
27 Increased shRNA abundance (Z-score > 2) GR00366-A-27 10.07 AIRE
28 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.07 CHRNA1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-33 10.07 ACHE
30 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.07 TNFSF13B
31 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.07 TNFSF13B
32 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.07 CHRNA1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.07 CHRNA1 MUSK
34 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.07 IL10
35 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.07 IL10 TNFSF13B
36 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.07 CHRNA1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.07 CHRNA1 MUSK
38 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.07 IL10
39 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.07 IL10
40 Increased shRNA abundance (Z-score > 2) GR00366-A-68 10.07 IL10
41 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.07 CHRNA1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.07 ACHE
43 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.07 AIRE
44 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.07 IL10
45 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.07 IL10 MUSK
46 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.07 RAPSN

MGI Mouse Phenotypes related to Myasthenia Gravis:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.37 ACHE AGRN AIRE AKAP12 CHRNA1 CHRNE
2 homeostasis/metabolism MP:0005376 10.35 ACHE AGRN AIRE CHRNG CTLA4 IFNG
3 growth/size/body region MP:0005378 10.33 ACHE AGRN AIRE AKAP12 CHRNE CHRNG
4 muscle MP:0005369 10.29 ACHE AGRN AKAP12 CHRNE CHRNG IFNG
5 behavior/neurological MP:0005386 10.24 ACHE AGRN AIRE AKAP12 CHRNA1 CHRNE
6 normal MP:0002873 10.2 AGRN AIRE AKAP12 CTLA4 IFNG IL10
7 immune system MP:0005387 10.13 ACHE AIRE AKAP12 CTLA4 IFNG IL10
8 respiratory system MP:0005388 10.13 ACHE AGRN AIRE AKAP12 CHRNE CHRNG
9 liver/biliary system MP:0005370 10.1 AIRE AKAP12 CTLA4 IFNG IL10 IL2
10 digestive/alimentary MP:0005381 10.09 AIRE CTLA4 IFNG IL10 IL2 IL4
11 no phenotypic analysis MP:0003012 10.08 ACHE AIRE IFNG IL10 IL2 IL4
12 hematopoietic system MP:0005397 9.97 ACHE AIRE AKAP12 CTLA4 IFNG IL10
13 craniofacial MP:0005382 9.95 ACHE IFNG IL10 IL4 RYR1 TNF
14 mortality/aging MP:0010768 9.91 ACHE AGRN AIRE AKAP12 CHRNA1 CHRNE
15 integument MP:0010771 9.28 CHRNG CTLA4 IFNG IL10 IL4 MUSK

Drugs & Therapeutics for Myasthenia Gravis

Drugs for Myasthenia Gravis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Salbutamol Approved, Vet_approved Phase 2, Phase 3 18559-94-9 2083
2
Eculizumab Approved, Investigational Phase 3 219685-50-4
3
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643
4
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
5
Mycophenolic acid Approved, Investigational Phase 3 24280-93-1 446541
6
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
7
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 3 14838-15-4, 492-39-7 131954576 4786 26934
8
Rituximab Approved Phase 3 174722-31-7
9
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
10
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
11
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
12
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
13
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
14
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 3 133585-56-5, 556-02-5, 60-18-4 1153 6057
15
Rozanolixizumab Investigational Phase 3 1584645-37-3
16 Adrenergic Agonists Phase 2, Phase 3
17 Adrenergic Agents Phase 2, Phase 3
18 Bronchodilator Agents Phase 2, Phase 3
19 Tocolytic Agents Phase 2, Phase 3
20 Anti-Asthmatic Agents Phase 2, Phase 3
21 Adrenergic beta-Agonists Phase 2, Phase 3
22 Anti-Infective Agents Phase 3
23 Calcineurin Inhibitors Phase 3
24 gamma-Globulins Phase 3
25 Rho(D) Immune Globulin Phase 3
26 Immunoglobulins, Intravenous Phase 3
27 Vaccines Phase 3
28 Antitubercular Agents Phase 3
29 Antibiotics, Antitubercular Phase 3
30 Anti-Bacterial Agents Phase 3
31 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
32 Immunologic Factors Phase 3
33 Antineoplastic Agents, Immunological Phase 3
34 Antirheumatic Agents Phase 3
35 Immunoglobulin G Phase 3
36 Antibodies, Monoclonal Phase 3
37 Immunosuppressive Agents Phase 3
38 Complement System Proteins Phase 3
39 glucocorticoids Phase 3
40 Antineoplastic Agents, Hormonal Phase 3
41 Hormones Phase 3
42 Hormone Antagonists Phase 3
43 Anti-Inflammatory Agents Phase 3
44
Pyridostigmine Bromide Phase 3 101-26-8
45
Racephedrine Approved, Experimental Phase 1, Phase 2 299-42-3, 90-82-4, 90-81-3 5032 9294 7028
46
Apraclonidine Approved Phase 2 66711-21-5 2216
47
Belimumab Approved Phase 2 356547-88-1
48
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 596 6253 6175
49
Etoposide Approved Phase 2 33419-42-0 36462
50
Carmustine Approved, Investigational Phase 2 154-93-8 2578

Interventional clinical trials:

(show top 50) (show all 156)
# Name Status NCT ID Phase Drugs
1 Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis Unknown status NCT03510546 Phase 4 Pyridostigmine;Placebo oral capsule
2 A Randomized Trial of Plasma Exchange vs. IVIG in the Treatment of Myasthenia Gravis Completed NCT01179893 Phase 4
3 Comparison of Two Tapering Strategies of Prednisone in Patients With Generalised Myasthenia Gravis Treated With Prednisone and Azathioprine: a Single-blind Randomised Controlled Multicenter Study Completed NCT00987116 Phase 4 Prednisone - Azathioprine
4 Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis Unknown status NCT03914638 Phase 2, Phase 3 Salbutamol 4Mg Tablet;Placebo oral capsule
5 A Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Safety and Efficacy of Rituximab (Mabthera®) in Patients With New Onset Generalized Myasthenia Gravis (MG) Unknown status NCT02950155 Phase 3 Rituximab;Sodium Chloride solution
6 A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients Completed NCT03304054 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
7 The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Completed NCT01727193 Phase 3 Azathioprine;Leflunomide
8 A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efgartigimod PH20 SC With Multiple Intravenous Infusions of Efgartigimod in Patients With Generalized Myasthenia Gravis Completed NCT04735432 Phase 3
9 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness Completed NCT03669588 Phase 3
10 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG) Completed NCT01997229 Phase 3 Placebo
11 IVIG Treatment Compared to Placebo in Patients With Myasthenia Gravis: A Randomized Clinical Trial Completed NCT00306033 Phase 3 Intravenous ImmuneGlobulin
12 A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone Completed NCT00294658 Phase 3 prednisone alone
13 A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness Completed NCT03770403 Phase 3
14 A Randomized, Controlled Clinical Study of GB-0998 for Treatment of Generalized Myasthenia Gravis Completed NCT00515450 Phase 3
15 FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients Completed NCT00309088 Phase 3 tacrolimus;placebo
16 A Trial of Mycophenolate Mofetil in Myasthenia Gravis Completed NCT00285350 Phase 3 mycophenolate mofetil
17 A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis Completed NCT04115293 Phase 3 zilucoplan (RA101495);Placebo
18 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, 36-Week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symptom Control With Reduced Corticosteroid in Subjects With Myasthenia Gravis Completed NCT00683969 Phase 3 mycophenolate mofetil (CellCept);placebo
19 A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Completed NCT04124965 Phase 3 Rozanolixizumab
20 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Completed NCT03971422 Phase 3 Rozanolixizumab
21 A Randomized, Double-blinded, Placebo-controlled, and Multi-centered Clinical Trial Evaluating the Efficacy and Safety of Tacrolimus Capsule in Myasthenia Gravis That Was Insufficiently Treated by Glucocorticoid Therapy Completed NCT01325571 Phase 3 Tacrolimus capsule;Placebo
22 A Randomized, Double-Blind Study to Evaluate the Safety of Continued Treatment With CellCept in Patients With Well-Controlled Myasthenia Gravis Receiving a Stable Dose of Prednisone Completed NCT00408213 Phase 3 mycophenolate mofetil [CellCept];Placebo
23 A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations Completed NCT02413580 Phase 3
24 A Phase III, Open-label Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG) Completed NCT02301624 Phase 3 Placebo
25 FK506 Phase 3 Study: An Open Study for Steroid Resistant, Non-Thymectomized MG Patients Completed NCT00309101 Phase 3 tacrolimus
26 Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Symptomatic Generalized Myasthenia Gravis Recruiting NCT05070858 Phase 3 Pozelimab + Cemdisiran;Cemdisiran;Pozelimab
27 Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis Recruiting NCT04833894 Phase 2, Phase 3
28 A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX-113-2006 to Evaluate Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis Recruiting NCT05374590 Phase 2, Phase 3
29 Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis Recruiting NCT04951622 Phase 3 Nipocalimab;Placebo
30 A Multicenter, Randomized, Double-blind, Placebo-controlled, Seamless and Group Sequential Phase 2/3 Study to Evaluate the Efficacy and Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis Recruiting NCT05039190 Phase 3 HBM9161 Injection (680mg);Placebos
31 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis Recruiting NCT04963270 Phase 3 Satralizumab
32 A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis Recruiting NCT04980495 Phase 3
33 A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG) Recruiting NCT05403541 Phase 3 Batoclimab 680 mg SC weekly;Batoclimab 340 mg SC weekly;Matching Placebo SC;Batoclimab 340 mg SC bi-weekly
34 A Pilot Trial To Assess The Feasibility And Efficacy Of Subcutaneous Immunoglobulin In Patients With Myasthenia Gravis Exacerbation Recruiting NCT02774239 Phase 3 Human normal immunoglobulin G (IgG)
35 An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis Recruiting NCT05265273 Phase 2, Phase 3 Nipocalimab
36 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis Recruiting NCT05556096 Phase 3
37 A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis Recruiting NCT04524273 Phase 3 inebilizumab;IV Placebo
38 Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis Recruiting NCT05332587 Phase 3 Rituximab
39 An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients With Refractory Generalized Myasthenia Gravis Active, not recruiting NCT03759366 Phase 3 Eculizumab
40 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tolebrutinib (SAR442168) in Adults With Generalized Myasthenia Gravis (MG) Active, not recruiting NCT05132569 Phase 3 Tolebrutininb;Placebo
41 An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis Active, not recruiting NCT04650854 Phase 3 Rozanolixizumab
42 Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis Active, not recruiting NCT03579966 Phase 3 Amifampridine Phosphate
43 A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis Active, not recruiting NCT04225871 Phase 3 zilucoplan (RA101495)
44 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis Active, not recruiting NCT03920293 Phase 3 Placebo
45 A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis Active, not recruiting NCT04818671 Phase 3
46 A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan Not yet recruiting NCT05514873 Phase 3 zilucoplan (RA101495)
47 A Long-term Open-label Extension Study to Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis Not yet recruiting NCT05332210 Phase 3 HBM9161 Injection (680mg);HBM9161 Drug Product (340mg)
48 Efficacy of Prednisone In the Treatment of Ocular Myasthenia: The EPITOME' Study Terminated NCT00995722 Phase 3 Prednisone;Placebo
49 A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis. Withdrawn NCT03165435 Phase 2, Phase 3
50 Ephedrine for the Treatment of Congenital Myasthenia Unknown status NCT00541216 Phase 1, Phase 2 Ephedrine

Search NIH Clinical Center for Myasthenia Gravis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cyclophosphamide
Cyclosporine
Neostigmine
Neostigmine bromide
Neostigmine Methylsulfate
Pyridostigmine
Pyridostigmine Bromide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myasthenia Gravis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myasthenia Gravis:
Hematopoietic stem cells for refractory myasthenia gravis
Embryonic/Adult Cultured Cells Related to Myasthenia Gravis:
Peripheral blood-derived hematopoietic stem cells

Cochrane evidence based reviews: myasthenia gravis

Genetic Tests for Myasthenia Gravis

Genetic tests related to Myasthenia Gravis:

# Genetic test Affiliating Genes
1 Myasthenia Gravis 28

Anatomical Context for Myasthenia Gravis

Organs/tissues related to Myasthenia Gravis:

MalaCards : Thymus, Eye, Skeletal Muscle, T Cells, Bone Marrow, B Cells, Thyroid

Publications for Myasthenia Gravis

Articles related to Myasthenia Gravis:

(show top 50) (show all 17350)
# Title Authors PMID Year
1
Myasthenia Gravis. 62 57
28029925 2016
2
An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. 62 57
17687331 2007
3
Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. 62 57
15843529 2005
4
Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. 62 57
12417565 2002
5
Myasthenia gravis in a woman with congenital AChR deficiency due to epsilon-subunit mutations. 62 57
12034803 2002
6
The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. 62 57
10711889 2000
7
Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. 62 57
10606626 1999
8
Immunogenetic heterogeneity and associated autoimmune disorders in myasthenia gravis: a population-based survey in the province of Ferrara, northern Italy. 62 57
7887131 1994
9
Familial autoimmune myasthenia gravis. 62 57
7908425 1994
10
Familial autoimmune myasthenia gravis with different pathogenetic antibodies. 62 57
3225607 1988
11
Myasthenia gravis in monozygotic twins. Clinical follow-up nine years after thymectomy. 62 57
6541031 1984
12
Heterozygous C2-deficiency and myasthenia gravis. 62 57
7191069 1980
13
Gm allotypes in myasthenia gravis. 62 57
6103092 1980
14
Clinical syndromes of myasthenia in infancy and childhood. A review. 62 57
341864 1978
15
A genetic study of infantile and juvenile myasthenia gravis. 62 57
5026010 1972
16
Familial myasthenia gravis. Report of 27 patients in 12 families and review of 164 patients in 73 families. 62 57
5146412 1971
17
Genetic study of sample of 70 patients with myasthenia gravis. 62 57
4976972 1968
18
Familial myasthenia gravis. 62 57
6036434 1967
19
Myasthenia gravis occurring in families. 62 57
5948009 1966
20
MYASTHENIA GRAVIS IN TWO SIBLINGS. 62 57
14237778 1965
21
Unusual familial occurrence of myasthenia gravis. 62 57
13823698 1960
22
Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis. 62 41
36083490 2022
23
Clinical characteristics of ocular myasthenia gravis and outcomes of secondary generalisation: a systematic review protocol. 62 41
36127086 2022
24
Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018. 62 41
36129914 2022
25
The use of sugammadex in a patient with myasthenia gravis. 53 62
20105151 2010
26
Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications. 53 62
20138518 2010
27
Structure-activity relationship of quaternary acetylcholinesterase inhibitors - outlook for early myasthenia gravis treatment. 53 62
20345342 2010
28
A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis. 53 62
19675582 2010
29
The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. 53 62
19693092 2009
30
[Mediation of cellular immune response by TP5 in pathogenesis of myasthenia gravis]. 53 62
20193562 2009
31
Myasthenia gravis patients with anti-MuSK antibodies. 53 62
20102061 2009
32
Methylacridinium and its cholinergic properties. 53 62
19565307 2009
33
The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. 53 62
19745065 2009
34
[Effects of acetylcholinesterase inhibitors on patients with MuSK antibody positive myasthenia gravis]. 53 62
19999149 2009
35
Immunocapture and identification of cell membrane protein antigenic targets of serum autoantibodies. 53 62
19332416 2009
36
Autoimmune disorders of the neuromuscular junction. 53 62
19428298 2009
37
Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. 53 62
19587811 2009
38
Acetylcholinesterase inhibitors in MG: to be or not to be? 53 62
19260048 2009
39
Interleukin-10 promoter polymorphisms in myasthenia gravis. 53 62
19299022 2009
40
Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. 53 62
19187062 2009
41
Muscle-specific receptor tyrosine kinase antibody-positive and seronegative myasthenia gravis. 53 62
19349708 2009
42
Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. 53 62
18728167 2008
43
A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. 53 62
18852352 2008
44
Hypothetical review: thymic aberrations and type-I interferons; attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes. 53 62
18727623 2008
45
Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation. 53 62
18684515 2008
46
Identification of CTLA-4 isoforms produced by alternative splicing and their association with myasthenia gravis. 53 62
18595775 2008
47
Serum BAFF expression in patients with myasthenia gravis. 53 62
18586330 2008
48
Muscle-specific kinase (MuSK) antibody-associated myasthenia gravis after bone marrow transplantation. 53 62
18537145 2008
49
Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor. 53 62
18657424 2008
50
[Thymopentin 5 in treatment of relapse after extended thymectomy: a randomized comparative clinical trial of 135 patients with myasthenia gravis]. 53 62
19087694 2008

Variations for Myasthenia Gravis

Expression for Myasthenia Gravis

Search GEO for disease gene expression data for Myasthenia Gravis.

Pathways for Myasthenia Gravis

Pathways related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.56 TNF IL4 IL2 IL10 IFNG
2 12.49 TNFSF13B TNF IL4 IL2 IL10 IFNG
3
Show member pathways
12.15 TNF IL4 IL2 IFNG
4 12.07 TNF IL4 IL10 IFNG
5
Show member pathways
11.98 TNF IL4 IL2 IL10 IFNG CTLA4
6 11.97 TNF IL4 IL2 IL10 IFNG
7
Show member pathways
11.9 TNF IL2 IL10 IFNG
8 11.76 TNF IL2 IL10 IFNG
9 11.76 TNF IL4 IL2 IL10 IFNG
10 11.72 IL4 IL2 IFNG
11 11.72 IL4 IL2 IL10 IFNG
12 11.7 IL2 IL10 IFNG
13 11.69 TNFSF13B TNF MBP IL4 IL2 IFNG
14
Show member pathways
11.67 CHRNG CHRNE CHRNA1
15 11.66 IL4 IL2 IFNG
16 11.65 IFNG IL10 IL2 IL4 TNF
17
Show member pathways
11.61 TNF IL2 IFNG
18 11.61 RAPSN MUSK CHRNA1 AGRN
19 11.6 TNFSF13B TNF IL10
20
Show member pathways
11.59 TNF IL4 IL2 IFNG CTLA4
21 11.52 TNF IL4 IL2 IL10 IFNG
22 11.5 IFNG IL10 IL2 IL4
23
Show member pathways
11.43 TNF IL4 IL2 IL10 IFNG
24 11.4 TNF IL4 IL2 IL10 IFNG CTLA4
25
Show member pathways
11.35 TNF IL2 IL10 IFNG
26 11.31 IFNG IL2 IL4
27 11.29 TNF IL4 IFNG
28 11.19 IL4 IL2 IL10 IFNG
29 10.99 TNFSF13B TNF MUSK IL4 IL2 IL10
30 10.94 IL4 IL2 IFNG
31 10.82 RYR1 CHRNE CHRNA1
32 10.72 IL2 IFNG CTLA4
33 10.48 TNF IL4 IL2 IL10 IFNG

GO Terms for Myasthenia Gravis

Cellular components related to Myasthenia Gravis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005887 10.34 TNF RYR1 MUSK CTLA4 CHRNG CHRNE
2 plasma membrane GO:0005886 10.34 TNF RYR1 MUSK CTLA4 CHRNG CHRNE
3 postsynaptic membrane GO:0045211 9.81 CHRNA1 CHRNE CHRNG MUSK RAPSN
4 synapse GO:0045202 9.8 RAPSN MUSK MBP CHRNG CHRNE CHRNA1
5 cellular anatomical entity GO:0110165 9.65 CTLA4 CHRNG CHRNE CHRNA1 AKAP12
6 neuromuscular junction GO:0031594 9.32 RAPSN MUSK CHRNE CHRNA1 ACHE

Biological processes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.49 AGRN AKAP12 CHRNA1 CHRNE CHRNG IFNG
2 chemical synaptic transmission GO:0007268 10.25 RAPSN MBP CHRNG CHRNE CHRNA1
3 positive regulation of B cell proliferation GO:0030890 10.08 TNFSF13B IL4 IL2
4 positive regulation of chemokine production GO:0032722 10.07 TNF IFNG AIRE
5 neuromuscular junction development GO:0007528 10.01 MUSK CHRNA1 AGRN
6 muscle contraction GO:0006936 10.01 TTN RYR1 CHRNG CHRNE
7 type 2 immune response GO:0042092 9.91 IL4 IL10
8 neuroinflammatory response GO:0150076 9.91 IL4 IFNG
9 microglial cell activation GO:0001774 9.91 TNF IL4 IFNG
10 positive regulation of mononuclear cell migration GO:0071677 9.88 TNF IL4
11 negative regulation of cytokine production involved in immune response GO:0002719 9.87 TNF IL10
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 TNF IL4 IL2 IFNG
13 B cell costimulation GO:0031296 9.83 IL4 TNFSF13B
14 regulation of isotype switching GO:0045191 9.81 IL10 IL4
15 positive regulation of plasma cell differentiation GO:1900100 9.8 IL2 IL10
16 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.78 TNF IFNG
17 regulation of postsynaptic membrane potential GO:0060078 9.76 CHRNG CHRNE CHRNA1
18 positive regulation of nitrogen compound metabolic process GO:0051173 9.76 TNF IFNG
19 chronic inflammatory response to antigenic stimulus GO:0002439 9.67 IL10 TNF
20 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL4 IL10 IFNG
21 positive regulation of vitamin D biosynthetic process GO:0060557 9.62 IFNG TNF
22 synaptic transmission, cholinergic GO:0007271 9.56 RAPSN CHRNG CHRNE CHRNA1
23 immune response GO:0006955 9.47 TNFSF13B TNF MBP IL4 IL2 IL10

Molecular functions related to Myasthenia Gravis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 excitatory extracellular ligand-gated ion channel activity GO:0005231 9.85 CHRNG CHRNE CHRNA1
2 ion channel activity GO:0005216 9.72 RYR1 CHRNG CHRNE CHRNA1
3 acetylcholine-gated cation-selective channel activity GO:0022848 9.63 CHRNG CHRNE CHRNA1
4 extracellular ligand-gated ion channel activity GO:0005230 9.43 CHRNG CHRNE CHRNA1
5 acetylcholine receptor activity GO:0015464 9.43 CHRNG CHRNE CHRNA1
6 cytokine activity GO:0005125 9.4 TNFSF13B TNF IL4 IL2 IL10 IFNG

Sources for Myasthenia Gravis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....